N. Greilert-Norin

发表

Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time

S. Hober, J. Klingström, M. Phillipson, 2022, Clinical & translational immunology.

Impact of SARS-CoV-2 infection on longitudinal vaccine immune responses

S. Hober, J. Klingström, K. Blom, 2021, medRxiv.

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection

S. Hober, J. Klingström, K. Blom, 2022, The New England journal of medicine.

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection

H. Tegel, M. Hedhammar, S. Hober, 2021, medRxiv.

Long‐term SARS‐CoV‐2‐specific and cross‐reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

P. Dönnes, H. Tegel, M. Hedhammar, 2022, Immunity, inflammation and disease.

Neutralization of VOCs including Delta one year post COVID-19 or vaccine

S. Hober, K. Blom, M. Åberg, 2021, medRxiv.

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection

S. Hober, J. Klingström, K. Blom, 2023, The Lancet Infectious Diseases.

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19

P. Dönnes, H. Tegel, M. Hedhammar, 2021, Journal of internal medicine.

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

S. Hober, J. Klingström, M. Phillipson, 2022, Vaccines.

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

S. Hober, J. Klingström, C. Hellström, 2021, EBioMedicine.

High prevalence of olfactory disorders 18 months after contracting COVID-19

M. Olsson, E. Thunell, S. Havervall, 2022, medRxiv.